ReviewInternational journal of urology : official journal of the Japanese Urological Association2025
Current Progress of Tissue Engineering With Stem Cells in Urology Updated Review in 2025.
Review in International journal of urology : official journal of the Japanese Urological Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Defining Uroplastics as a Collaborative Discipline at the Interface of Urology and Plastic Surgery.Plastic and reconstructive surgery. Global open · 2026Article
- Current Progress of Tissue Engineering With Stem Cells in Urology Updated Review in 2025.International journal of urology : official journal of the Japanese Urological Association · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tissue engineering, a key component of regenerative medicine, aims to restore the structure and function of damaged organs using combinations of cells, scaffolds, and bioactive factors. In urology, the integration of stem cell biology has fueled significant progress in preclinical models for kidney, bladder, and urethral regeneration. Pluripotent stem cells, such as embryonic stem cells and induced pluripotent stem cells, offer broad differentiation potential, particularly in kidney organoid development. Meanwhile, multipotent stem cells-especially mesenchymal stem cells and urine-derived stem cells-have shown promise in bladder and urethral repair due to their immunomodulatory properties and relative ease of use. Despite these advancements, certain challenges remain: vascularization, functional integration, long-term safety, and scalability continue to limit the clinical application of regenerated organs. In kidney regeneration, issues such as nephron-collecting duct connectivity and urinary outflow remain unresolved. For the bladder and urethra, the need for vascularized, contractile, and innervated tissue complicates scaffold and cell selection. Nonetheless, clinical translation is becoming increasingly realistic. As the field evolves rapidly, it is essential for urologists to remain informed and actively engage in collaborative research. By integrating clinical expertise with basic science, urologists can play a crucial role in guiding regenerative strategies toward effective, patient-specific therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.